一贯煎及其加减方治疗慢性肝病的研究进展  

Research Progress of Yiguan Jian Decoction and Its Additive and Subtractive Formula in the Treatment of Chronic Liver Diseases

作　　者：刘雪辉 郑云飞 张雪巍 李伟[2] 邓鑫[1,2] 

机构地区：[1]广西中医药大学研究生院,广西 南宁 [2]广西中医药大学附属瑞康医院,广西 南宁

出　　处：《中医学》2024年第12期3433-3439,共7页Traditional Chinese Medicine

基　　金：广西中医药大学“桂派中医药传承创新团队”(桂科2022B004)。

摘　　要：文章借助相关文献综述了一贯煎及其加减方在慢性肝病治疗中的研究进展,探讨了该方剂在肝纤维化、肝硬化及肝癌等疾病中的作用机制和临床效果。一贯煎由北沙参、麦冬、当归、生地黄、枸杞子和川楝子六味药材组成,在临床研究上可通过调控RhoA/ROCK1、Notch1、SMAD2/3等信号通路,起到抗炎、抗纤维化、免疫调节及促进肝细胞再生等出色疗效,极大程度上改善患者的生活质量和延长生存期。然而,当前研究仍集中于基础实验和临床观察,缺乏大规模随机对照试验及系统的分子机制探讨。未来研究需进一步验证其临床疗效并探索其潜在副作用。In this paper, the research progress of the Yiguan Jian decoction and the modified formulas in the treatment of chronic liver disease and the mechanism and clinical effect of this prescription in liver fibrosis, cirrhosis and liver cancer are discussed. The decoction consists of radix glehniae, ophiopogon, Angelica sinensis, Rehmannia root, barbary wolfberry, and Melia toosendan. In clinical research, it can promote anti-inflammatory, anti-fibrosis, immune regulation, and hepatocyte regeneration by regulating signaling pathways such as RhoA/ROCK1, Notch1, and SMAD2/3. Greatly improves patients’ quality of life and prolongs survival. However, the current research still focuses on basic experiments and clinical observation, and there is a lack of large-scale randomized controlled trials and systematic exploration of molecular mechanisms. Future studies are needed to further verify its clinical efficacy and explore its potential side effects.

关 键 词：一贯煎 肝纤维化 肝硬化 肝癌 研究进展 

分 类 号：R28[医药卫生—中药学]